tiprankstipranks
Sinopharm Group Co (SHTDY)
OTHER OTC:SHTDY
Holding SHTDY?
Track your performance easily

Sinopharm Group Co (SHTDY) Income Statement

21 Followers

Sinopharm Group Co Income Statement

Last quarter (Q2 2022), Sinopharm Group Co's total revenue was ¥261.47B, an increase of 28.32% from the same quarter last year. In Q2, Sinopharm Group Co's net income was ¥―. See Sinopharm Group Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
¥ 1.49T¥ 521.05B¥ 456.41B¥ 425.02B¥ 344.30B¥ 307.67B
Cost of Revenue
-¥ 477.00B¥ 416.09B¥ 387.74B¥ 313.30B¥ 282.30B
Gross Profit
-¥ 44.05B¥ 40.32B¥ 37.28B¥ 31.01B¥ 25.36B
Operating Expense
-¥ 22.61B¥ 20.54B¥ 19.03B¥ 15.47B¥ 12.81B
Operating Income
-¥ 21.44B¥ 19.78B¥ 18.50B¥ 15.53B¥ 12.55B
Net Non Operating Interest Income Expense
-¥ -3.40B¥ -2.94B¥ -3.14B¥ -2.77B¥ -2.08B
Other Income Expense
------
Pretax Income
-¥ 17.00B¥ 15.60B¥ 13.76B¥ 12.21B¥ 11.23B
Tax Provision
-¥ 3.94B¥ 3.50B¥ 3.14B¥ 2.80B¥ 2.56B
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-¥ 7.76B¥ 7.19B¥ 6.25B¥ 5.83B¥ 5.57B
Basic EPS
-¥ 12.45¥ 11.55¥ 10.55¥ 9.85¥ 9.40
Diluted EPS
-¥ 12.45¥ 11.55¥ 10.50¥ 9.80¥ 9.40
Basic Average Shares
-¥ 624.13M¥ 622.26M¥ 593.93M¥ 593.53M¥ 593.06M
Diluted Average Shares
-¥ 624.13M¥ 622.26M¥ 594.33M¥ 594.33M¥ 594.33M
Dividend Per Share
-¥ 3.48¥ 2.97¥ 2.94¥ 2.90¥ 2.48
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-¥ 499.61B¥ 436.63B¥ 406.77B¥ 328.77B¥ 295.11B
Net Income From Continuing And Discontinued Operation
-¥ 7.76B¥ 7.19B¥ 6.25B¥ 5.84B¥ 5.58B
Normalized Income
-¥ 9.44B¥ 8.96B¥ 8.17B¥ 7.07B¥ 5.37B
Interest Expense
-¥ 3.76B¥ 3.42B¥ 3.44B¥ 3.07B¥ 2.80B
EBIT
-¥ 20.76B¥ 19.02B¥ 17.20B¥ 15.28B¥ 14.02B
EBITDA
-¥ 24.68B¥ 22.62B¥ 17.20B¥ 16.67B¥ 15.27B
Currency in CNY

Sinopharm Group Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis